153 related articles for article (PubMed ID: 37856781)
1. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract][Full Text] [Related]
2. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
[TBL] [Abstract][Full Text] [Related]
3. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
[TBL] [Abstract][Full Text] [Related]
5. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
6. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
[TBL] [Abstract][Full Text] [Related]
7. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
[TBL] [Abstract][Full Text] [Related]
9. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S; Cheong HS; Kim JO; Kim LH; Na HS; Koh IS; Chung MW; Shin HD
Environ Toxicol Pharmacol; 2015 Nov; 40(3):692-7. PubMed ID: 26409184
[TBL] [Abstract][Full Text] [Related]
10. Association of Tissue Abiraterone Levels and
Mostaghel EA; Cho E; Zhang A; Alyamani M; Kaipainen A; Green S; Marck BT; Sharifi N; Wright JL; Gulati R; True LD; Loda M; Matsumoto AM; Tamae D; Penning TN; Balk SP; Kantoff PW; Nelson PS; Taplin ME; Montgomery RB
Clin Cancer Res; 2017 Aug; 23(16):4592-4601. PubMed ID: 28389510
[No Abstract] [Full Text] [Related]
11. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
[TBL] [Abstract][Full Text] [Related]
12. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
[TBL] [Abstract][Full Text] [Related]
13. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
[TBL] [Abstract][Full Text] [Related]
14. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.
Green SM; Kaipainen A; Bullock K; Zhang A; Lucas JM; Matson C; Banks WA; Mostaghel EA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):20-27. PubMed ID: 27645128
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
[TBL] [Abstract][Full Text] [Related]
16. Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
Jayalath VH; Clark R; Lajkosz K; Fazelzad R; Fleshner NE; Klotz LH; Hamilton RJ
JAMA Netw Open; 2022 Nov; 5(11):e2242676. PubMed ID: 36449294
[TBL] [Abstract][Full Text] [Related]
17. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A; Niemi M
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):9-13. PubMed ID: 20560925
[TBL] [Abstract][Full Text] [Related]
19. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
